Xenon Pharmaceuticals, Inc. Q4 FY2024 earnings call

Key Highlights

• 2024 Accomplishments: Advancement of azetukalner in Phase 3 epilepsy program, launch of Phase 3 MDD program, planning for azetukalner in bipolar depression, and progress in discovery portfolio with molecules entering clinical trials.
• Pipeline Progress: Azetukalner's Phase 3 epilepsy studies (X-TOLE in focal onset seizures, X-ACKT in primary generalized tonic-clonic seizures) with first focal onset seizures top-line data expected in H2 2025; Phase 3 MDD program with X-NOVA2 enrolling and X-NOVA3 starting mid-2025; initiation of registrational program for azetukalner in bipolar depression; progress in early stage ion channel programs (Kv7 and Nav1.7).
• Clinical Development: AES presence highlighting mental health burdens in epilepsy; ongoing X-TOLE open-label extension study showing sustained seizure reduction and safety; MDD Phase 2 proof-of-concept study enrollment complete, top-line results expected in H1 2025.
• Market Research: Bipolar depression market research with psychiatrists showing interest in azetukalner's attributes like once-daily dosing and novel mechanism.

No specific product segment financial performance data with absolute revenue and contribution % provided in the transcript.

Forward-Looking Statements

• Phase 3 Epilepsy: First focal onset seizures top-line data expected in H2 2025, with NDA filing anticipated post-data.
• MDD: X-NOVA2 enrolling, X-NOVA3 to start mid-2025; Phase 2 MDD study top-line results expected in H1 2025.
• Bipolar Depression: Registrational program to initiate mid-2025.
• Cash Runway: Sufficient cash to fund operations into 2027.

Risks

• Regulatory Uncertainty: Potential delays in regulatory interactions or approvals.
• Clinical Trial Risks: Possibility of failing to meet efficacy or safety endpoints in trials.
• Competition: Impact of other treatments on azetukalner's market potential.

Question and Answer

Q: On Phase 3 epilepsy enrollment and bipolar depression guidance A: Ian and Chris discussed Phase 3 epilepsy data expected in H2 2025, and the strong genetic and clinical rationale for bipolar depression.

Q: Bipolar depression study design A: Chris clarified that studies will include both bipolar I and II patients, with more details to come on trial design.

Q: Azetukalner's best-in-class threshold and MDD Phase 2 data A: Ian mentioned success in Phase 3 epilepsy is about achieving statistical significance for NDA submission, and the Phase 2 MDD study will provide data on secondary endpoints like MADRS and SHAPS.

Q: Xcopri comparison and sodium channel modulators A: Sherry and Ian discussed Xcopri's profile vs azetukalner's benefits, and plans for sodium channel programs to enter IND and conduct proof-of-concept studies.

Q: BPD program details and NAV 1.1 A: Ian and Chris talked about BPD study design details and NAV 1.1's potential in Dravet syndrome and other epilepsies.

Q: Azetukalner's early adopters and R&D spend A: Chris and Sherry discussed early adopters from prescriber perspective and R&D spend factored into the cash runway projection.